GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (STU:BPXA) » Definitions » Cyclically Adjusted Price-to-FCF

Bellicum Pharmaceuticals (STU:BPXA) Cyclically Adjusted Price-to-FCF : (As of Jun. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bellicum Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Bellicum Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bellicum Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Bellicum Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellicum Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Bellicum Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Bellicum Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Bellicum Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.046/129.8595*129.8595
=-0.046

Current CPI (Sep. 2023) = 129.8595.

Bellicum Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -1.581 98.326 -2.088
201403 -2.384 99.695 -3.105
201406 -2.315 100.560 -2.990
201409 -0.385 100.428 -0.498
201412 -15.548 99.070 -20.380
201503 -2.800 99.621 -3.650
201506 -3.710 100.684 -4.785
201509 -3.138 100.392 -4.059
201512 -4.493 99.792 -5.847
201603 -4.520 100.470 -5.842
201606 -5.155 101.688 -6.583
201609 -4.170 101.861 -5.316
201612 -5.582 101.863 -7.116
201703 -8.235 102.862 -10.396
201706 -7.038 103.349 -8.843
201709 -5.188 104.136 -6.470
201712 -3.661 104.011 -4.571
201803 -4.626 105.290 -5.706
201806 -4.146 106.317 -5.064
201809 -3.352 106.507 -4.087
201812 -4.190 105.998 -5.133
201903 -4.939 107.251 -5.980
201906 -4.211 108.070 -5.060
201909 -3.614 108.329 -4.332
201912 -2.293 108.420 -2.746
202003 -2.925 108.902 -3.488
202006 -2.532 108.767 -3.023
202009 -2.246 109.815 -2.656
202012 -1.375 109.897 -1.625
202103 -0.694 111.754 -0.806
202106 -0.640 114.631 -0.725
202109 -0.083 115.734 -0.093
202112 -0.339 117.630 -0.374
202203 -0.188 121.301 -0.201
202206 -0.202 125.017 -0.210
202209 -0.193 125.227 -0.200
202212 -0.212 125.222 -0.220
202303 -0.195 127.348 -0.199
202306 -0.239 128.729 -0.241
202309 -0.046 129.860 -0.046

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bellicum Pharmaceuticals  (STU:BPXA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Bellicum Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellicum Pharmaceuticals (STU:BPXA) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (STU:BPXA) Headlines

No Headlines